“Best Practice in Personalised Medicine” Recognition 2021 – now open for applications

The International Consortium for Personalised Medicine launched its fourth Recognition. The objective of the ICPerMed Recognition 2021 is to honour, encourage, promote and disseminate outstanding evidence-based applications in the field of personalised medicine (PM), focusing on the implementation of PM research. The deadline for proposal submission will be 18 February 2022.

The Recognition is open to candidates worldwide, who have published scientific papers (paper accepted by the respective editor) and/or developed best practice strategies (training programmes or interdisciplinary/intersectoral groups of collaboration) for implementation of PM approaches between 1 November 2019 and 31 December 2020. Applications concerning an ongoing or recently accomplished training or collaboration need to be accompanied by a supporting documentation. The submission including the documents to be evaluated (single-stage evaluation) will only be accepted in English and only one submission per applicant is possible.

In 2022, those applications addressing outstanding PM outcomes will be announced as winners and will be invited to present their approaches during the next ICPerMed Event. The winners will be honoured by a 500 € non-cash value support for dissemination.

Further details on the ICPerMed “Best Practice in Personalised Medicine” Recognition 2021 and on the application process is available here:

Call for Applications

Application Form

01.27.2022 note: The deadline for proposal submission is postponed to 18 February 2022.

For further questions please contact healthresearch(at)


ANR and ICPerMed

ICPerMed was established in November 2016 and comprises over 40 European and international members representing research and health ministries as well as funding agencies, including the European Commission as observer. The aim of ICPerMed is to boost personalised medicine by an enhanced coordination and alignment of research activities.

The French National Research Agency (ANR) is implicated in ICPerMed as well as in the Coordination and Support Action ICPerMed Secretariat (CSA ICPerMed Secretariat), ERA PerMed, the ERA Net on Personalised Medicine, and EU-Africa PerMed.

Last updated on 27 January 2022
Sign up for the latest news:
Subscribe to our newsletter